Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Minerva Neurosciences, Inc is a biotechnology business based in the US. Minerva Neurosciences shares (NERV) are listed on the NASDAQ and all prices are listed in US Dollars. Minerva Neurosciences employs 13 staff and has a trailing 12-month revenue of around USD$41.2 million.
|Latest market close||USD$2.66|
|52-week range||USD$2.51 - USD$15.215|
|50-day moving average||USD$3.3989|
|200-day moving average||USD$4.0281|
|Wall St. target price||USD$6.9|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.375|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-13)||N/A|
|1 month (2020-12-24)||8.13%|
|3 months (2020-10-20)||N/A|
|6 months (2020-07-20)||N/A|
|1 year (2020-01-20)||N/A|
|2 years (2019-01-20)||N/A|
|3 years (2018-01-20)||N/A|
|5 years (2016-01-20)||N/A|
|Revenue TTM||USD$41.2 million|
|Gross profit TTM||USD$0|
|Return on assets TTM||-3%|
|Return on equity TTM||-36.38%|
|Market capitalisation||USD$110.5 million|
TTM: trailing 12 months
There are currently 2.5 million Minerva Neurosciences shares held short by investors – that's known as Minerva Neurosciences's "short interest". This figure is 14% down from 2.9 million last month.
There are a few different ways that this level of interest in shorting Minerva Neurosciences shares can be evaluated.
Minerva Neurosciences's "short interest ratio" (SIR) is the quantity of Minerva Neurosciences shares currently shorted divided by the average quantity of Minerva Neurosciences shares traded daily (recently around 373807.58928571). Minerva Neurosciences's SIR currently stands at 6.72. In other words for every 100,000 Minerva Neurosciences shares traded daily on the market, roughly 6720 shares are currently held short.
However Minerva Neurosciences's short interest can also be evaluated against the total number of Minerva Neurosciences shares, or, against the total number of tradable Minerva Neurosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Minerva Neurosciences's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Minerva Neurosciences shares in existence, roughly 60 shares are currently held short) or 0.0832% of the tradable shares (for every 100,000 tradable Minerva Neurosciences shares, roughly 83 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Minerva Neurosciences.
Find out more about how you can short Minerva Neurosciences stock.
We're not expecting Minerva Neurosciences to pay a dividend over the next 12 months.
Over the last 12 months, Minerva Neurosciences's shares have ranged in value from as little as $2.51 up to $15.215. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Minerva Neurosciences's is 1.527. This would suggest that Minerva Neurosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.